LNK01002 for Acute Myeloid Leukemia

"Affirmative. Clinicaltrials.gov records suggest that this clinical trial, which was initially publicised on April 8th 2021, is still open for enrolment. Approximately 93 patients are needed to be recruited from two separate sites/institutions."

"The requirements to be accepted into this trial specify that the patient must have an age of 18 or above and below 99. There are 451 studies for patients younger than 18, and 1333 trials targeting those over 65 years old."

"This clinical trial is recruiting 93 individuals between the ages of 18 and 99 who are diagnosed with primary myelofibrosis. Furthermore, these patients must meet Intermediate or High-Risk PMF criteria, have symptomatic splenomegaly, not had a splenectomy in the past 6 months, and women of childbearing potential need to take a pregnancy test at screening. Additionally, any female patient capable of bearing children or male participants along with their partners must agree to use effective contraception during the study's duration and for six months after completion."

"The safety of LNK01002 was determined to be a 1 due to the Phase 1 status of this trial, which only provides limited data demonstrating efficacy and minimal evidence supporting its security."

"Across the span of 31 days, this clinical trial will assess the preliminary anti-tumor efficacy of LNK01002. Additionally, it seeks to measure pharmacokinetic parameters like CL/F, MRT and Vz/F using extensive PK sampling in patients with myelofibrosis (MF), post-essential thrombocythemia MF (ET-MF) or polycythaemia vera associated MF (PV-MF)."

"Indeed, clinicaltrials.gov suggests that the trial is in progress and recruiting participants. Initially posted on 8th April 2021, it was last modified on 5th June 2021 with a recruitment goal of 93 patients from 2 locations."